RACHEL KING: Open Payments
NPI 1205826245 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,745 in 21 payments from 7 companies in 2025. Trend: 2023 $592 · 2024 $1,253 · 2025 $1,745
Consulting: $1,140Food & beverage: $436Education: $169
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 5 | $1,252 |
| Novartis Pharmaceuticals Corporation | 9 | $230 |
| Janssen Biotech, Inc. | 3 | $107 |
| SANOFI-AVENTIS U.S. LLC | 1 | $97 |
| GENZYME CORPORATION | 1 | $23 |
| Galderma Laboratories, L.P. | 1 | $22 |
| Amgen Inc. | 1 | $14 |
Products named: Bimzelx, Rhapsido, DUPIXENT, TREMFYA, XOLAIR, NEMLUVIO, OTEZLA.
Industry payments across ID — which companies pay providers there.
